Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Phase II Study
100%
Elderly Patients
100%
R-THP-COP
100%
Treatment Regimen
80%
5-year Survival
40%
Prognostic Factors
40%
Rituximab
20%
Combination Therapy
20%
Prednisolone
20%
Doxorubicin
20%
Cardiotoxicity
20%
Aged 80 Years and over
20%
Adriamycin
20%
Cyclophosphamide
20%
Complete Remission
20%
Poor Prognostic Factors
20%
CD20-negative
20%
Pirarubicin
20%
Anthracycline Antibiotics
20%
Nursing and Health Professions
Elderly Patient
100%
Diffuse Large B Cell Lymphoma
100%
Survival Rate
40%
Doxil
40%
Side Effect
20%
Combination Therapy
20%
Remission
20%
Prednisolone
20%
Vincristine
20%
Pirarubicin
20%
Anthracycline
20%
Rituximab
20%
Cyclophosphamide
20%
Sphingolipid Activator Protein 2
20%
Cardiotoxicity
20%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
100%
Survival Rate
50%
Doxorubicin
50%
Vincristine
25%
Combination Therapy
25%
Side Effect
25%
Prednisolone
25%
Anthracycline
25%
Cardiotoxicity
25%
Cyclophosphamide
25%
Rituximab
25%
Remission
25%
Sphingolipid Activator Protein 2
25%
Pirarubicin
25%